Aluminium-or calcium-based phosphate-binding agents traditionally have been used to treat
hyperphosphataemia in patients with end-stage renal disease. Although these agents …

Phosphate-binder therapy for hyperphosphataemia is key to the treatment of patients with
chronic kidney disease (CKD)-mineral and bone disorder (MBD). Calcium-free phosphate …

Treating hyperphosphatemia without increasing the calcium load in chronic kidney disease
patients on dialysis is important, as conventional treatment frequently results in ectopic …

Abstract Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective
phosphate binder for which tolerability and a safety profile have been reported in …

Background. Lanthanum carbonate (LC) has been proposed as a new phosphate binder.
Presented here are the results from one centre that participated in a multicentre trial to …

Despite 10 years of post‐marketing safety monitoring of the phosphate binder lanthanum
carbonate, concerns about aluminium‐like accumulation and toxicity persist. Here, we …

Background. Hyperphosphataemia in dialysis patients is associated with significant
morbidity. We assessed the ability of lanthanum carbonate to control phosphate levels in …

Importance Among patients with hyperphosphatemia undergoing dialysis, it is unclear
whether non–calcium-based phosphate binders are more effective than calcium-based …

A multicenter study on the affects of lanthanum carbonate (Fosrenol™) and calcium
carbonate on renal bone disease in dialysis patients. Background Lanthanum carbonate …

Background Serum phosphorus control is critical for chronic kidney disease (CKD) 5D
patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese …